Ebola virus dynamics in mice treated with favipiravir

Antiviral Research

Volumn 123, Issue , 2015, Pages 70-77

  Madelain, Vincent ^a,b   Oestereich, Lisa ^c,d   Graw, Frederik ^e   Nguyen, Thi Huyen Tram ^a,b   De Lamballerie, Xavier ^f,g   Mentré, France ^a,b   Günther, Stephan ^c,d   Guedj, Jeremie ^a,b  

^a UNIVERSITÉ PARIS DIDEROT   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c BERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE   (Germany)

^d German Centre for Infection Research (DZIF)   (Germany)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f Aix Marseille University IRD 190 Inserm 1207   (France)

^g AIX MARSEILLE UNIVERSITY   (France)

Author keywords

Ebola; Favipiravir; Modeling; Viral kinetics

Indexed keywords

FAVIPIRAVIR; AMIDE; ANTIVIRUS AGENT; PYRAZINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; ARTICLE; BACTERIAL GROWTH; BASIC REPRODUCTION NUMBER; COMPARTMENT MODEL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; EBOLA HEMORRHAGIC FEVER; EBOLAVIRUS; FEMALE; HILL COEFFICIENT; LIMIT OF QUANTITATION; MAXIMUM DRUG EFFECT; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRAL CLEARANCE; VIROGENESIS; VIRUS LOAD; VIRUS REPLICATION; VOLUME OF DISTRIBUTION; ANIMAL; C57BL MOUSE; DISEASE MODEL; GROWTH, DEVELOPMENT AND AGING; HEMORRHAGIC FEVER, EBOLA; ISOLATION AND PURIFICATION; SURVIVAL ANALYSIS; THEORETICAL MODEL; VIROLOGY;

AMIDES; ANIMALS; ANTIVIRAL AGENTS; DISEASE MODELS, ANIMAL; EBOLAVIRUS; FEMALE; HEMORRHAGIC FEVER, EBOLA; MICE, INBRED C57BL; MODELS, THEORETICAL; PYRAZINES; SURVIVAL ANALYSIS; VIRAL LOAD;

EID: 84941351827     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2015.08.015     Document Type: Article

References (24)

1. P. Baccam, C. Beauchemin, C.A. Macken, F.G. Hayden, and A.S. Perelson Kinetics of influenza A virus infection in humans J. Virol. 80 2006 7590 7599
2. C.A.A. Beauchemin, and A. Handel A review of mathematical models of influenza A infections within a host or cell culture: lessons learned and challenges ahead BMC Public Health 11 Suppl. 1 2011 S7
3. L. Canini, and A.S. Perelson Viral kinetic modeling: state of the art J. Pharmacokinet. Pharmacodyn. 41 2014 431 443
4. A. Chatterjee, J. Guedj, and A.S. Perelson Mathematical modeling of HCV infection: what can it teach us in the era of direct antiviral agents? Antiviral Ther. 17 2012 1171 1182
5. H. Feldmann, and T.W. Geisbert Ebola haemorrhagic fever Lancet 377 2011 849 862
6. Y. Furuta, K. Takahashi, M. Kuno-Maekawa, H. Sangawa, S. Uehara, K. Kozaki, N. Nomura, H. Egawa, and K. Shiraki Mechanism of action of T-705 against influenza virus Antimicrob. Agents Chemother. 49 2005 981 986
7. T.W. Geisbert Emergency treatment for exposure to Ebola virus: the need to fast-track promising vaccines JAMA 313 2015 1221 1222
8. T.W. Geisbert, L.E. Hensley, P.B. Jahrling, T. Larsen, J.B. Geisbert, J. Paragas, H.A. Young, T.M. Fredeking, W.E. Rote, and G.P. Vlasuk Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys Lancet 362 2003 1953 1958
9. B.B. Gowen, E.J. Sefing, J.B. Westover, D.F. Smee, J. Hagloch, Y. Furuta, and J.O. Hall Alterations in favipiravir (T-705) pharmacokinetics and biodistribution in a hamster model of viral hemorrhagic fever Antiviral Res. 121 2015 132 137
10. J. Guedj, H. Dahari, L. Rong, N.D. Sansone, R.E. Nettles, S.J. Cotler, T.J. Layden, S.L. Uprichard, and A.S. Perelson Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life Proc. Natl. Acad. Sci. U.S.A. 110 2013 3991 3996
11. F. Mentré, A.-M. Taburet, J. Guedj, X. Anglaret, S. Keïta, X. de Lamballerie, and D. Malvy Dose regimen of favipiravir for Ebola virus disease Lancet Infect. Dis. 15 2015 150 151
12. M. Mohamadzadeh, L. Chen, and A.L. Schmaljohn How Ebola and Marburg viruses battle the immune system Nat. Rev. Immunol. 7 2007 556 567
13. A.U. Neumann, N.P. Lam, H. Dahari, D.R. Gretch, T.E. Wiley, T.J. Layden, and A.S. Perelson Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy Science 282 1998 103 107
14. L. Oestereich, A. Lüdtke, S. Wurr, T. Rieger, C. Muñoz-Fontela, and S. Günther Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model Antiviral Res. 105 2014 17 21
15. J. Olejnik, E. Ryabchikova, R.B. Corley, and E. Mühlberger Intracellular events and cell fate in filovirus infection Viruses 3 2011 1501 1531
16. A.S. Perelson Modelling viral and immune system dynamics Nat. Rev. Immunol. 2 2002 28 36
17. A.S. Perelson, and J. Guedj Modelling hepatitis C therapy-predicting effects of treatment Nat. Rev. Gastroenterol. Hepatol. 12 2015 437 445
18. J. Pinheiro, and D. Bates Mixed-Effects Models in S and S-PLUS 2006 Springer Science & Business Media
19. D. Safronetz, T.W. Geisbert, and H. Feldmann Animal models for highly pathogenic emerging viruses Curr. Opin. Virol. 3 2013 205 209
20. Sissoko, D., Anglaret, X., Malvy, D., Folkesson, E., Abdoul, M., Shepherd, S., Danel, C., Beavogui, A.H., Gunther, S., Mentre, F., 2015. Favipiravir in patients with Ebola virus disease: early results of the JIKI trial in Guinea. In: Presented at the CROI 2015, Abstract Number 103-ALB, Seattle, Washington, USA.
21. A.M. Smith, and A.S. Perelson Influenza A virus infection kinetics: quantitative data and models Wiley Interdiscip. Rev. Syst. Biol. Med. 3 2011 429 445
22. A.M. Smith, F.R. Adler, J.L. McAuley, R.N. Gutenkunst, R.M. Ribeiro, J.A. McCullers, and A.S. Perelson Effect of 1918 PB1-F2 expression on influenza A virus infection kinetics PLoS Comput. Biol. 7 2011 e1001081
23. S.J. Smither, L.S. Eastaugh, J.A. Steward, M. Nelson, R.P. Lenk, and M.S. Lever Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model Antiviral Res. 104 2014 153 155
24. M.A. Stafford, L. Corey, Y. Cao, E.S. Daar, D.D. Ho, and A.S. Perelson Modeling plasma virus concentration during primary HIV infection J. Theor. Biol. 203 2000 285 301